These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 11410275

  • 1. Inactivation of CMY-2 beta-lactamase by tazobactam: initial mass spectroscopic characterization.
    Bonomo RA, Liu J, Chen Y, Ng L, Hujer AM, Anderson VE.
    Biochim Biophys Acta; 2001 Jun 11; 1547(2):196-205. PubMed ID: 11410275
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 -->Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition.
    Pagan-Rodriguez D, Zhou X, Simmons R, Bethel CR, Hujer AM, Helfand MS, Jin Z, Guo B, Anderson VE, Ng LM, Bonomo RA.
    J Biol Chem; 2004 May 07; 279(19):19494-501. PubMed ID: 14757767
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of OXA-1 beta-lactamase by penems.
    Bethel CR, Distler AM, Ruszczycky MW, Carey MP, Carey PR, Hujer AM, Taracila M, Helfand MS, Thomson JM, Kalp M, Anderson VE, Leonard DA, Hujer KM, Abe T, Venkatesan AM, Mansour TS, Bonomo RA.
    Antimicrob Agents Chemother; 2008 Sep 07; 52(9):3135-43. PubMed ID: 18559643
    [Abstract] [Full Text] [Related]

  • 5. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
    Bethel CR, Taracila M, Shyr T, Thomson JM, Distler AM, Hujer KM, Hujer AM, Endimiani A, Papp-Wallace K, Bonnet R, Bonomo RA.
    Antimicrob Agents Chemother; 2011 Jul 07; 55(7):3465-75. PubMed ID: 21555770
    [Abstract] [Full Text] [Related]

  • 6. Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.
    Endimiani A, Doi Y, Bethel CR, Taracila M, Adams-Haduch JM, O'Keefe A, Hujer AM, Paterson DL, Skalweit MJ, Page MG, Drawz SM, Bonomo RA.
    Biochemistry; 2010 Feb 09; 49(5):1014-23. PubMed ID: 19938877
    [Abstract] [Full Text] [Related]

  • 7. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
    Kalp M, Totir MA, Buynak JD, Carey PR.
    J Am Chem Soc; 2009 Feb 18; 131(6):2338-47. PubMed ID: 19161282
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of TEM-2 beta-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry.
    Brown RP, Aplin RT, Schofield CJ.
    Biochemistry; 1996 Sep 24; 35(38):12421-32. PubMed ID: 8823177
    [Abstract] [Full Text] [Related]

  • 9. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
    Totir MA, Cha J, Ishiwata A, Wang B, Sheri A, Anderson VE, Buynak J, Mobashery S, Carey PR.
    Biochemistry; 2008 Apr 01; 47(13):4094-101. PubMed ID: 18324783
    [Abstract] [Full Text] [Related]

  • 10. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
    Helfand MS, Bethel CR, Hujer AM, Hujer KM, Anderson VE, Bonomo RA.
    J Biol Chem; 2003 Dec 26; 278(52):52724-9. PubMed ID: 14534312
    [Abstract] [Full Text] [Related]

  • 11. N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam.
    Skalweit MJ, Li M, Conklin BC, Taracila MA, Hutton RA.
    Antimicrob Agents Chemother; 2013 Apr 26; 57(4):1596-602. PubMed ID: 23318801
    [Abstract] [Full Text] [Related]

  • 12. Identification of products of inhibition of GES-2 beta-lactamase by tazobactam by x-ray crystallography and spectrometry.
    Frase H, Smith CA, Toth M, Champion MM, Mobashery S, Vakulenko SB.
    J Biol Chem; 2011 Apr 22; 286(16):14396-409. PubMed ID: 21345789
    [Abstract] [Full Text] [Related]

  • 13. Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.
    Padayatti PS, Sheri A, Totir MA, Helfand MS, Carey MP, Anderson VE, Carey PR, Bethel CR, Bonomo RA, Buynak JD, van den Akker F.
    J Am Chem Soc; 2006 Oct 11; 128(40):13235-42. PubMed ID: 17017804
    [Abstract] [Full Text] [Related]

  • 14. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
    Padayatti PS, Helfand MS, Totir MA, Carey MP, Carey PR, Bonomo RA, van den Akker F.
    J Biol Chem; 2005 Oct 14; 280(41):34900-7. PubMed ID: 16055923
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam.
    Kuzin AP, Nukaga M, Nukaga Y, Hujer A, Bonomo RA, Knox JR.
    Biochemistry; 2001 Feb 13; 40(6):1861-6. PubMed ID: 11327849
    [Abstract] [Full Text] [Related]

  • 16. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes.
    Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y.
    Antimicrob Agents Chemother; 1993 Apr 13; 37(4):851-8. PubMed ID: 8388201
    [Abstract] [Full Text] [Related]

  • 17. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.
    Totir MA, Padayatti PS, Helfand MS, Carey MP, Bonomo RA, Carey PR, van den Akker F.
    Biochemistry; 2006 Oct 03; 45(39):11895-904. PubMed ID: 17002290
    [Abstract] [Full Text] [Related]

  • 18. Characterization of a PSE-4 mutant with different properties in relation to penicillanic acid sulfones: importance of residues 216 to 218 in class A beta-lactamases.
    Sabbagh Y, Thériault E, Sanschagrin F, Voyer N, Palzkill T, Levesque RC.
    Antimicrob Agents Chemother; 1998 Sep 03; 42(9):2319-25. PubMed ID: 9736556
    [Abstract] [Full Text] [Related]

  • 19. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.
    Padayatti PS, Helfand MS, Totir MA, Carey MP, Hujer AM, Carey PR, Bonomo RA, van den Akker F.
    Biochemistry; 2004 Feb 03; 43(4):843-8. PubMed ID: 14744126
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
    Therrien C, Kotra LP, Sanschagrin F, Mobashery S, Levesque RC.
    FEBS Lett; 2000 Mar 31; 470(3):285-92. PubMed ID: 10745083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.